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Generating conditional gene 
knockouts in Plasmodium – a 
toolkit to produce stable DiCre 
recombinase-expressing parasite 
lines using CRISPR/Cas9
Ellen Knuepfer1, Marta Napiorkowska2,3, Christiaan van Ooij  2 & Anthony A. Holder1
Successful establishment of CRISPR/Cas9 genome editing technology in Plasmodium spp. has provided 
a powerful tool to transform Plasmodium falciparum into a genetically more tractable organism. 
Conditional gene regulation approaches are required to study the function of gene products critical for 
growth and erythrocyte invasion of blood stage parasites. Here we employ CRISPR/Cas9 to facilitate 
use of the dimerisable Cre-recombinase (DiCre) that is frequently used to mediate the excision and 
loss of loxP-flanked DNA sequences in a rapamycin controlled manner. We describe novel CRISPR/Cas9 
transfection plasmids and approaches for the speedy, stable and marker-free introduction of transgenes 
encoding the DiCre recombinase into genomic loci dispensable for blood stage development. Together 
these plasmids form a toolkit that will allow the rapid generation of transgenic DiCre-expressing P. 
falciparum lines in any genetic background. Furthermore, the newly developed 3D7-derived parasite 
lines, constitutively and stably expressing DiCre, generated using this toolkit will prove useful for the 
analysis of gene products. Lastly, we introduce an improved treatment protocol that uses a lower 
rapamycin concentration and shorter treatment times, leading to loxP-guided recombination with close 
to 100% efficiency within the same replication cycle.
Malaria is one of the most significant infectious diseases of people in low income countries, with an estimated 
212 million cases in 2015 causing around half a million deaths. 99% of these deaths occur as a consequence of 
P. falciparum infections, in particular affecting children below the age of five in Africa1. The fast spread of drug 
resistance2 and the limited efficacy of current vaccines3 highlight the pressing need to identify new targets for 
therapeutic intervention. In 2002, the genome sequence of the 3D7 line of P. falciparum was published4. It encodes 
roughly 5400 genes, half of which have no assigned function, in part due to the limited sequence similarity with 
genes outside of the Plasmodium genus.
Recently, the CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR-associated 
protein 9) genome editing system has been successfully adapted for use in Plasmodium spp., revolutionising 
genetic engineering in these parasites5–7.
The parasite is haploid for much of its life cycle, including during the asexual erythrocytic cycle, requiring 
conditional genetic modification systems to study essential gene functions. Such systems allowing for control 
over mRNA abundance and stability, translation, and protein turnover have been developed but these approaches 
often result in only partial depletion of the gene product8–11. As a consequence, results from these studies can be 
difficult to interpret. A recent report describes protein mislocalisation induced by addition of a small molecule 
as a new conditional system to study protein functions in P. falciparum12, allowing the investigation of proteins 
that can be modified at the N terminus or C terminus and are not secreted. In other organisms site-specific 
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recombinases are widely used to modify genomes, for example the total removal of a target gene or an important 
part thereof. The use of Cre- and FLP-recombinase has been described in Plasmodium spp.13–16. The inducible Cre 
recombinase (DiCre) established for use in P. falciparum uses the rapamycin-binding FKBP12 and FRB proteins 
to dimerise the two enzyme halves17; this system was first established in Apicomplexan parasites in Toxoplasma 
gondii18 and then adapted successfully to P. falciparum13, 14. This site–specific recombinase recognises short, 34 bp 
sequences called loxP sites and catalyses the excision or inversion of the floxed (flanked by loxP) DNA segment. 
LoxP sites can be introduced silently within the ORF in the form of an artificial intron (loxPint)19, or can be intro-
duced into endogenous introns or into UTRs. Conditional excision of DNA sequences flanked by loxP sites can 
be designed such that in addition to removal of DNA sequences, domain swaps, introduction of point mutations 
and fusions to epitope tags can be generated.
The DiCre system has already been used to study the functions of gene products suspected to be essential for 
asexual blood stage development. Conditional knockouts of genes coding for MSP1, AMA1, RIPR, CyRPA, and 
PFA0210c have been generated, showing severe growth impairment that could not have been discovered using 
other methods14, 20–22.
Different systems have been developed to introduce DiCre into P. falciparum, including integration of DiCre 
cassettes into the chromosome and expression of the genes from an episome. Excision levels vary greatly between 
the systems, ranging from 50–98%13, 14, 20, 21. The integrated version of the system in the 3D7-derived 1G5DC 
parasite line tends to provide higher excision levels, but requires experimentation in that particular genetic 
background. In addition the 1G5DC line is subject to loss of the DiCre cassettes due to genetic reversion as the 
initial introduction of the DiCre cassettes has been generated through single cross-over recombination23. The 
episome-based expression of DiCre allows the DiCre system to be introduced in different parasite lines, but often 
provides lower excision levels.
Here we describe a toolkit of CRISPR/Cas9 and rescue plasmids to enable the quick, stable and marker-free 
generation of DiCre-expressing P. falciparum parasites. We demonstrate this by inserting DiCre recombinase into 
two loci, p230p and pfs47, which are dispensable for blood stage development as well as for infectivity to mosqui-
toes. In addition to the generation of the new DiCre recombinase-expressing parasite lines we have optimised the 
use of rapamycin for induction of Cre-recombinase activity. Lower concentrations of rapamycin for shorter expo-
sure periods resulted in close to 100% excision within the same replication cycle. Using this toolkit to generate 
DiCre recombinase-expressing parasite lines will broaden the use of this conditional system, providing unrivalled 
levels of gene regulation in Plasmodium well beyond the 3D7 parasite line.
Results
Optimisation of rapamycin use to induce DiCre-mediated recombination activity. The rapa-
mycin-inducible DiCre recombinase system has been used successfully for site-specific recombination in 
Plasmodium spp., resulting in deletion of whole or partial ORFs or UTRs13, 14, 19–21. In these studies, parasite cul-
tures were treated with 100 nM rapamycin for a minimum of four hours and high levels of excision of floxed DNA 
sequence were reported. However, both rapamycin and the carrier, DMSO, can negatively affect parasite growth 
at higher concentrations. Using an already established floxed PFA0210c (PF3D7_0104200) line22, generated in the 
DiCre-expressing parasite line 1G5DC13, we set out to establish the lowest concentration of rapamycin required 
to achieve maximum excision levels.
We treated PFA0210c-loxP parasites at early ring stage with 0, 3.3, 10, 33 or 100 nM rapamycin for between 
30 min and 4 h and isolated genomic DNA 38–40 h later. PCR amplification of the PFA0210c-loxP locus revealed 
successful excision, as indicated by the decrease in size of the PCR product from 1580 bp to 562 bp, for all rapa-
mycin concentrations of 10 nM and higher (Fig. 1a, b). Only in parasites treated with the lowest concentration of 
rapamycin (3.3 nM) did we detect a significant level of the unexcised locus. No difference was detected between 
treatment for 30 min and 4 h (Fig. 1b). We conclude that treatment with 10 nM rapamycin for 30 min, the shortest 
treatment period tested, is sufficient to induce maximum excision.
Comparing the previously used standard treatment to our newly determined minimal rapamycin exposure 
to achieve maximal DiCre recombinase activity, we examined recombination during the course of the lifecycle 
on parasites treated with 10 nM rapamycin for 30 minutes or 100 nM rapamycin for four hours. We determined 
the level of excision at 6 time points in one ~48-hour replication cycle (Fig. 1c,d). First, we observed no obvious 
difference in the degree of excision between the two treatment conditions at any time point. Second, a substan-
tial level of excision was detected 20 h after the start of rapamycin treatment, with the maximum level achieved 
after 30 h. This result is in agreement with previously published data14, 17 and indicates that rapamycin-induced 
DiCre-mediated recombination is a slow process even if the formation of the Cre recombinase appears to be fast, 
as excision continues even after the removal of rapamycin.
New CRISPR/Cas9 plasmids for stable insertion of DiCre recombinase into the Plasmodium 
falciparum genome. The previously available DiCre-expressing parasite line, 1G5DC, has proven to be an 
excellent tool to generate conditional gene modifications. However, this parasite line was generated by inserting 
the DiCre cassettes via single homologous recombination within the SERA locus on chromosome 2, resulting in 
duplication of 940 bp of SERA5 DNA sequence13. We and others have detected occasional spontaneous reversion 
in these parasites to the wild type SERA5 locus, resulting in the loss of the DiCre recombinase23 (Collins and 
Blackman, personal communication). To overcome this issue we applied a double homologous recombination 
approach using CRISPR/Cas9 gene editing to insert the DiCre cassette into one of two loci, p230p and pfs47, 
which have been validated as playing no role in the growth rate of P. falciparum asexual blood stages, or gameto-
cyte production24, 25.
To insert the transgenes into a defined locus in the P. falciparum genome we used the CRISPR/Cas9 DNA 
editing tool. SpCas9 nuclease derived from Streptococcus pyogenes is targeted to a defined position in the genome 
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by a single guide RNA, resulting in a DNA double-stranded break (DSB). DSB are normally lethal events unless 
repaired. Plasmodium parasites are deficient in DNA repair mechanisms such as canonical non-homologous end 
joining (C-NHEJ); instead the preferred repair mechanism is homologous recombination26. For this we provide 
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Figure 1. Optimisation of rapamycin-induced recombination. (a) Parasites containing a modified PFA0210c22 
were used to test DiCre-mediated recombination efficiency. For this a recodonised version of part of the ORF 
of PFA0210c was flanked by a loxPint sequence upstream and a loxP sequence downstream located within 
the endogenous locus on chromosome 1 in the 1G5DC parasite line. (b) The efficiency of excision was tested 
whilst altering the concentration and length of exposure to rapamycin (rapa). Either DMSO alone (0 nM) or 
increasing concentrations (in nM) of rapamycin were added to transgenic PFA0210c-loxP parasites as indicated 
for 4, 2, 1 h or 30 min. The degree of recombination was determined by PCR using primers 13 and 14 depicted 
as arrows in panel a). A lack of recombination and no excision resulted in a PCR product of 1580 bp (u) whereas 
successful excision resulted in a 562 bp product (e). The sizes of DNA markers (in kb) are depicted on the left. 
(c) The timing of excision was determined following addition of either 100 nM rapamycin for 4 h (100) or 10 nM 
rapamycin for 30 min (10) at very early ring stages. Parasites were harvested 2, 4, 8, 20, 30 or 44 h after the onset 
of treatment. Genomic DNA was extracted from saponin-treated parasite pellets and excision was determined 
by PCR as described in panel b. (d) Graph depicting the degree of excision (in %) over time elapsed after start of 
rapamycin treatment. For this graph, the data in panel c) was semi-quantitatively analysed. Pixel intensities of 
stained DNA bands were measured using ImageJ and the ratio of excised vs. unexcised was plotted against time 
after rapamycin addition, comparing two treatment methods (100 nM rapamycin for 4 h and 10 nM rapamycin 
for 30 min).
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a rescue plasmid containing DNA segments homologous in sequence to the target DNA close to the DSB site. 
Transfection of parasites with the CRISPR/Cas9 and the rescue plasmid results in exchange of DNA in the endog-
enous locus with a transgene flanked by the homologous DNA regions. Unlike single homologous recombination 
the vector backbone is not inserted into the chromosome and no duplication of homologous DNA sequences 
occurs in the genome.
Our CRISPR/Cas9 gene editing tool uses two plasmids that are co-transfected (Fig. 2). The first plas-
mid, pDC2-Cas9-hDHFRyFCU, encodes the SpCas9 nuclease and the single guide RNA and is derived from 
pDC2-Cas9-U6-hdhfr27. It was modified to contain a fusion of the positive selectable marker hDHFR (human 
dihydrofolate reductase) and the negative selectable marker yFCU (yeast cytosine deaminase/uridyl phosphor-
ibosyl transferase) (Supplementary Fig. S1). For this, we amplified the hdhfr-yfcu cassette from pL003428 using 
overlap extension PCR to destroy any BbsI restriction sites within the sequence. BbsI was used to insert the 
annealed guide RNA into the U6 promoter-terminator cassette resulting in seamless transcription of the single 
guide RNA. We reasoned that negative selection is desirable to select for parasites that have lost the CRISPR/Cas9 
plasmid containing the positive selection marker. The second plasmid is a rescue plasmid, and as in Lu et al.29, it 
contains no selectable marker, allowing for marker-free modifications. In this case it is a pBluescript-derived plas-
mid carrying the complete expression cassettes coding for the two polypeptides forming the DiCre-recombinase. 
These two transgene cassettes were flanked by homology sequences of 500 bp to 976 bp, giving rise to pBSp-
230pDiCre and pBSPfs47DiCre (Supplementary Fig. S2).
The sequences used for homologous recombination in pfs47 and p230p are based on the P. falciparum 3D7 
line. However, to make this toolkit universally suitable for generating DiCre-expressing parasites from any P. fal-
ciparum line, we aimed to select the most conserved DNA sequences as homology regions (HR), which have to be 
in close proximity to the site in which the DSB is induced. Pfs47 is polymorphic30 and therefore we examined sin-
gle nucleotide polymorphisms (SNPs) in the ORF and UTRs in sequences of field isolates and laboratory strains 
available on PlasmoDB (www.PlasmoDB.org) as well as exonic sequences from 3488 isolates from 23 countries 
on MalariaGen (www.malariagen.net/data/pf3k-4). In HR1 32 SNPs were identified in the 202 laboratory lines 
and field isolates sequenced and analysed on PlasmoDB. Of these only four SNPs had minor allele frequencies 
(MAF) above 1%, all others were below 1%. Cloning of the 851 bp HR1 of pfs47 from 3D7 resulted in six nucleo-
tide deletions in repetitive sequence elements compared to the published sequence, a 99.3% identity level. In HR2 
a total of 68 SNPs could be identified with 53 having a MAF of less than 1%, often only found in a single isolate. 
However, geographic region-specific haplotypes are apparent in lines derived from South America showing six 
SNPs with fixation or at near fixation frequencies, as well as in parasites originating from South East Asia with six 
SNPs, three of which are identical to those of the South American isolates (Supplementary Table S1). Of the lines 
listed in Supplementary Table S1 the highest number of SNPs in any line is 7, a 99.3% level of sequence identity to 
the HR2. Similarly for p230p, we selected homology regions with the minimum number of SNPs (Supplementary 
Table S2). The first region of homology chosen (500 bp in length) contained 38 SNPs in the Pf3K-4 dataset with 
35 of these showing a MAF of 0.1% or less. In the DNA region chosen as HR2 (644 bp in length) 83 SNPs were 
identified, with only 8 SNPs showing a MAF above 1% and the highest at 7%. To allow modifications in already 
WR99210-resistant strains we also developed a CRISPR/Cas9 vector containing a pac-yfcu selection cassette, 
allowing for positive selection using puromycin (Supplementary Fig. S3).
In order to direct the SpCas9 nuclease to target the p230p locus for a DSB, two guide RNA sequences were 
designed and inserted into the U6 cassette, resulting in two plasmids pDC115 and pDC120. For targeting pfs47 a 
single guide RNA was designed and cloned into pDC2-Cas9-hDHFRyFCU, resulting in pDC287. One SNP was 
identified in the DNA sequence used as guide RNA in pDC115 (C5613T) with a MAF of 0.1% and only detected 
in lines derived from Bangladesh, whereas the DNA sequence chosen as protospacer in pDC120 showed no SNPs. 
The protospacer sequence in pDC287 for targeting pfs47 carries two SNPs (G135C and T148C) with MAFs of 
0.4% and 0.5%, respectively.
Successful transgene integration into p230p and pfs47 will result in the disruption of either genomic locus, as 
depicted in Fig. 3a and b.
Cas9 sgRNA
hDHFR-yFCU
cam U6 
PbDT 
pDC2-Cas9-hDHFRyFCU
FKBPcre59 FRB cre60HR1 HR2
bip hsp86 
+
pBSp230pDiCre; 
pBSPfs47DiCre
Figure 2. Toolkit plasmids for efficient integration of DiCre recombinase into p230p or pfs47 loci of the 
P. falciparum genome. The CRISPR-Cas9 plasmid used here, pDC2-Cas9-hDHFRyFCU (derived from 
pDC2-Cas9-U6-hdhfr27) carries the SpCas9 nuclease gene and a single guide RNA cassette driven by a 
short U6 promoter and the hdhfr-yfcu fusion gene for selection. The rescue plasmids (pBSp230pDiCre and 
pBSPfs47DiCre) contain the genes for the split Cre-recombinase fused to FRB and FKBP12 respectively, flanked 
by regions of homology from the p230p or the pfs47 locus of P. falciparum. More detailed vector maps are 
available in Supplementary Fig. S2.
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For transfection, we used the Amaxa™ 4D-Nucleofector™ technology with purified 3D7 schizonts, 60 μg 
of linearised rescue plasmid, and 20 or 30 μg of the CRISPR/Cas9 plasmid carrying the respective guide RNA. 
Transfection of linear DNA is common practice for generating transgenic P. berghei and P. knowlesi parasites and 
has also been used successfully for P. falciparum5. This method has the advantage that linear DNA is not retained 
beyond 4 days post-transfection31 and for this reason and the marker-free approach chosen here, hDHFR selec-
tion with WR99210 was only applied for 4 days. Viable parasites were detected 14 d post-transfection and subse-
quently screened for integration by PCR and treated with 5-fluorocytosine (5-FC) for one week prior to cloning 
by limiting dilution. Eight out of 10 clones of the targeted integration into the pfs47 locus gave rise to bands of the 
expected sizes, whereas two out of 26 clones of the targeted integration into the p230p locus with either of the two 
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Figure 3. Successful generation of P. falciparum parasite lines expressing DiCre recombinase using CRISPR-
Cas9. (a) Schematic of wild type p230p ORF and modified ORF containing the DiCre recombinase expression 
cassettes following transfection of 3D7 with pBSp230pDiCre and pDC120 (pDC2-hDHFR-yFCU plasmid 
carrying the guide sequence). Homology regions (HRs) used for targeting were 500 bp (HR1) and 644 bp 
(HR2) in size. (b) Schematic of wild type pfs47 locus and modified, DiCre-expressing pfs47 locus. The blue box 
depicts the pfs47 ORF, and hashed boxes the DNA regions used for homologous repair. Transfection of 3D7 
with pBSPfs47DiCre and pDC287 (the plasmid carrying the guide sequence for Pfs47 targeting) resulted in the 
disruption of the pfs47 ORF. (c) PCR screen on wild type and transgenic parasite clones (II-3 and Pfs47-13) 
showing successful integration of the DiCre cassette into the targeted loci. Primer pairs 1/2 and 3/4 amplify 
fragments of p230p in wild type parasites only with expected sizes of 772 bp and 771 bp respectively. Primer 
pairs 1/5 and 4/6 amplify DNA only after successful integration into p230p with expected sizes of 947 bp and 
1229 bp respectively. Primer pairs 7/8 and 9/10 amplify 1042 bp and 1114 bp fragments from the pfs47 wild 
type locus only; whereas primer pairs 5/7 and 6/10 only amplify the expected 1257 bp and 1555 bp bands after 
successful integration. Primers used for amplification are shown on the top of each panel, as well as in the 
schematics in a) and b). DNA marker sizes are indicated on the left in kb.
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guide RNAs gave rise to the expected PCR products (Fig. 3c). Seven weeks following transfection we had success-
fully generated marker-free parasite clones with the desired integration of the DiCre-recombinase cassettes into 
the target genes. Further tests revealed that these clones were sensitive to WR99210, having lost the CRISPR/Cas9 
plasmid (data not shown). We selected one clone from each transfection for further analysis: II-3 (p230pDiCre) 
and Pfs47-13 (pfs47DiCre).
The pfs47DiCre and p230pDiCre Plasmodium falciparum lines allow efficient excision of 
loxP-flanked reporter constructs. To test whether these new DiCre recombinase transgenic parasites 
are able to mediate rapamycin-induced excision we transfected wild type 3D7 and the DiCre-expressing parasite 
lines 1G5DC, II-3 and Pfs47-13 with a GFP reporter plasmid in which gfp is flanked by loxP sites (Fig. 4a and 
Supplementary Fig. S4). Treatment of the DiCre-expressing reporter lines with rapamycin induced efficient exci-
sion of gfp as detected by PCR, immunoblot and fluorescence microscopy (Fig. 4b,c and Fig. 5a), irrespective of 
rapamycin treatment conditions (100 nM for 4 h or 10 nM for 1 h). Treatment of all reporter lines with DMSO 
and treatment of 3D7 parasites carrying the reporter plasmid with rapamycin did not induce excision and conse-
quently there was GFP expression.
To quantify the extent of excision we compared numbers of GFP-positive schizonts between DMSO and rapa-
mycin treatments of the same reporter line by flow cytometry. Excision within one replication cycle exceeded 
99% in II-3 and Pfs47-13 parasite lines, comparable to the level of excision measured for the established 1G5DC 
line (Fig. 5b). Equally, rapamycin treatment at lower concentrations and for shorter exposure times resulted in 
excision levels comparable to those using the standard treatment conditions.
We also investigated the potential for reversion in the DiCre transgenic reporter lines by PCR (Supplementary 
Fig. S5). II-3 and Pfs47-13 DiCre parasite lines generated by double homologous recombination following 
CRISPR/Cas9 induced DSBs showed no reversion at the p230p or pfs47 locus, respectively. On the other hand 
after three months in culture, PCR amplification from the 1G5DC reporter line showed a band corresponding to 
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Figure 4. The new transgenic parasite lines excise floxed DNA sequences efficiently. (a) Schematic of reporter 
plasmid pHH3-SP-loxPint-GFP-loxP. The gfp ORF is flanked by a loxPint site upstream and a loxP site 
downstream. Transcription is driven by 1258 bp of msp3 5′UTR sequence. SP, 110 bp of signal peptide-encoding 
sequence from msp3; bsd, blasticidin S deaminase driven by hsp86 promoter. 3D7, and the DiCre-expressing 
parasite lines 1G5DC, II-3 and Pfs47-13 were transfected with the reporter plasmid and selected using 
2.5 µg/ml blasticidin. (b) PCR amplification of the GFP cassette using primers 11 and 12 showing successful 
recombination after rapamycin treatment. The expected product size is 1471 bp before excision and 670 bp 
following excision. Treatment conditions were either 0.05% DMSO (0), 100 nM rapamycin for 4 h (100) or 
10 nM rapamycin for 1 h (10) as indicated on the top of each lane. The parasite lines treated are indicated at the 
bottom of the panel. DNA marker sizes are shown on the left. (c) Immunoblots showing the lack of a 27 kDa 
GFP band after rapamycin treatment. The four parasite lines transfected with the reporter plasmid were treated 
with DMSO or rapamycin as indicated on the top of each panel and described in section b). Treatment occurred 
at early ring stage and schizonts were harvested by Percoll gradient 38–40 h later before separation on SDS-
PAGE and immunoblotting. Anti-GFP and anti-MSP2 antibodies were used as indicated on the right of the 
panels.
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Figure 5. The new transgenic parasite lines expressing DiCre recombinase excise floxed DNA sequences 
with >99% efficiency using rapamycin at lower concentrations and short treatment times. (a) Live GFP 
fluorescence assay of wild type and DiCre transgenic parasite lines transfected with the reporter plasmid 
pHH3-SP-loxPint-GFP-loxP and treated at the early ring stage with DMSO or rapamycin as indicated on 
top of the panels. Images were taken 40 h later. Size bars equal 10 μm. (b) Excision efficiency determined by 
flow cytometry. The four parasite lines transfected with the reporter plasmid were treated with DMSO or 
rapamycin as described above and the number of GFP positive schizonts was counted 38–40 h after treatment. 
Data correspond to the mean and standard deviation (s.d.) calculated from three independent experiments 
counting 100,000 cells each time.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 3881  | DOI:10.1038/s41598-017-03984-3
an intact SERA5 locus, suggesting that over time the DiCre cassette is lost in part of the population. These results 
show that the new transgenic P. falciparum lines II-3 and Pfs47-13 stably maintain DiCre recombinase and excise 
loxP-flanked DNA sequences with extremely high efficiency even at a 10-fold lower rapamycin concentration 
than has been routinely used.
Discussion
The aim of this study was to develop a complete toolkit to generate rapamycin-inducible DiCre 
recombinase-expressing P. falciparum lines which efficiently and rapidly excise floxed DNA sequences in any 
genetic background.
CRISPR/Cas9 gene editing tools in Plasmodium spp. were first reported in 20145–7. Since then further improve-
ments to the system have been made, allowing for quick, marker-free generation of transgenic parasites. These 
techniques have proven a powerful tool, shortening the time from transfection to analysis of transgenic parasite 
clones by many months. Multiple successive rounds of gene modification in the same parasite are therefore now 
realistically achievable. In this study we have further improved the CRISPR/Cas9 system and transfection meth-
ods using linear DNA for marker-free modifications in P. falciparum, resulting typically in the generation of trans-
genic parasites and the isolation of clones lacking integrated drug selection cassettes in less than two months, the 
fastest method so far reported for P. falciparum. Our approach is similar to that of both Lu et al.29 and Mogollon 
et al.24. We have used two plasmids, a CRISPR/Cas9 plasmid encoding the single guide RNA and SpCas9 nuclease, 
and a rescue plasmid, carrying the regions for repair by homologous recombination. Plasmodium species, like a 
few other eukaryotic pathogens (Giardia lamblia, Trichomonas vaginalis and Trypanosoma brucei), lack efficient 
NHEJ as a DNA repair mechanism (reviewed in Lee et al.32), instead using almost exclusively homologous recom-
bination26, 33. Our CRISPR/Cas9 plasmid, pDC2-Cas9-hDHFRyFCU, carries a positive and a negative selection 
cassette in the form of a hdhfr-yfcu fusion gene, whereas the rescue plasmid is derived from pBluescript and 
carries no drug selection, allowing for the insertion of large DNA fragments. This system has the advantage that 
no selection marker is integrated into the chromosome and addition of 5-FC to cultures allows for the selection 
of parasites that have lost the CRISPR/Cas9 vector. In addition, we linearised the rescue plasmid for transfection 
to avoid potential maintenance as an episome even though it carries no drug resistance marker. To maximise the 
uptake of both plasmids into the same parasite we transfected a molar ratio of 2.5:1 to 4:1 of rescue to CRISPR/
Cas9 plasmids and only applied selection to the cultures for 4 days using WR99210. The use of hDHFR as a posi-
tive selection marker over blasticidin S deaminase (bsd) is preferable as no development of spontaneous resistance 
to WR99210 has been reported, whereas the use of blasticidin S can result in the selection for spontaneous blasti-
cidin S resistance in P. falciparum cultures34, 35.
Using this improved CRISPR/Cas9 system we generated functional DiCre recombinase-expressing 3D7 P. 
falciparum parasites by inserting the DiCre cassettes into the genomic locus of p230p and pfs47, yielding parasite 
lines called II-3 (p230pDiCre) and Pfs47-13 (pfs47DiCre), respectively. Using double homologous recombination 
for integration of the cassettes circumvents the possibility of spontaneous loss of the DiCre recombinase cassettes 
as seen in the 1G5DC line. Furthermore, the p230p and pfs47 loci were chosen as disruption of these genes does 
not alter asexual blood stage growth and development or gametocyte production24, 25. In fact, p230p in rodent 
malaria parasites also seems dispensable for development in the mosquito stages36. P. falciparum pfs47 knockout 
parasites have been described as developing in Anopheles stephensi but seem unable to establish successful infec-
tions in A. gambiae36, 37.
All DNA sequences chosen as homology regions contained SNPs, mostly with low MAFs. In 
laboratory-adapted lines the sequence disparity was less than 1% and we expect no difficulties in generating 
DiCre recombinase-expressing parasites in these using the plasmids described here26. Given the low MAFs of 
SNPs we equally expect these plasmids to be useful for generating DiCre-expressing parasite lines from field 
isolates. In fact, in the plasmid pBSPfs47DiCre the homology region one lacks six nucleotides compared to the 
published 3D7 sequence, a 99.3% identity level, and we achieved transgene integration in the pfs47 locus in 80% 
of the population after transfection. Targeting the p230p locus with either of two different guide RNAs was less 
efficient and resulted in only 8% of the clones carrying the DiCre cassettes. We attribute this difference in effi-
ciency of gene editing to the nature of the guide RNAs selected. We have used pDC-Cas9-hDHFRyFCU to modify 
numerous P. falciparum genes and found differences in efficiency in modifying a locus are dependent on the guide 
RNA sequences selected, a principle generally applicable for CRISPR/Cas9 gene editing38. We succeeded in our 
first attempt to integrate the transgenes into both the pfs47 and the p230p locus. Independent transfections tar-
geting the pfs47 locus by us and others resulted in 86% (n = 1) and 50 to 58% (n = 4) of clones expressing DiCre 
(Tiburcio and Treeck, personal communication). Together these data indicate that the plasmids in this toolkit 
allow for the efficient production of the desired DiCre recombinase-expressing parasite lines with minimal effort. 
When modifying field isolates, however, we suggest prior examination of the p230p or pfs47 DNA sequences, 
especially for guide RNA design to avoid possible SNPs, however rare.
The DiCre cassettes used in this study are based on those reported by Collins et al.13 that use the hsp86 and 
bip promoters to drive transcription of the split cre genes. Studies showing lower excision levels of 50 to 80% have 
maintained the DiCre-recombinase expression cassettes on episomes and used the hsp86 and ef1α promoters to 
drive transcription of the split cre genes. Although these promoters allow for constitutive transcription, the ef1α 
promoter is very weak compared to the hsp86 promoter, which probably does not allow sufficient DiCre recom-
binase expression early in the life cycle. Coordinated expression of both parts of the DiCre recombinase early in 
the life cycle appears to be crucial for extensive loxP-guided recombination12. This difference might explain the 
superior excision levels seen using the DiCre cassettes reported by Collins et al.13 and used here to generate our 
transgenic parasites II-3 and Pfs47-13.
The DiCre-recombinase system as a conditional gene regulation system is becoming more widely 
used. Tamoxifen-induced dimerisation of estrogen receptor binding domains fused to split Cre as well as 
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photoactivatable dimerisation have been used to bring both halves of the split Cre recombinase together to form 
an active recombinase in mice39, 40. The system established for P. falciparum uses the rapamycin-binding FKBP12 
and FRB proteins to dimerise the two enzyme halves. Rapamycin and also the carrier DMSO are toxic to P. falci-
parum at higher concentrations14, 41. For that reason we have established the lowest concentration of rapamycin 
and the shortest exposure time required to achieve maximal recombination levels: 10 nM rapamycin for 30 min. 
This protocol results in excision levels still exceeding 99% with no impact on parasite growth and is cheaper 
and more user-friendly compared to the standard treatment of 100 nM rapamycin for 4 h. We also wanted to 
understand whether the timing of excision after addition of rapamycin at early ring stages is affected by the 
concentration of rapamycin and exposure period. We detected no difference whether using a 10-fold higher 
rapamycin concentration for a longer period or the minimal treatment conditions we established here. In both 
cases it took about 20 h before significant levels of excision could be detected and more than 30 h to achieve 
maximum levels. A delay between rapamycin exposure and start of excision of floxed DNA sequences has been 
reported previously13, 14, 17. This delay could reduce the usefulness of this conditional regulation system for genes 
transcribed in the first 24 h of the life cycle. An example of this has been reported recently using conditional 
DiCre recombinase-mediated excision of kelch13 and rab5a12. After addition of rapamycin no Rab5a could be 
detected later in that cycle whereas Kelch13 persisted for at least two days, although at much reduced level. 
Kelch13 is transcribed in schizont and ring stages, whereas rab5a mRNA level seems to peak in trophozoite 
stages. Therefore translation of kelch13 was on going during DiCre recombinase induction, and for stable pro-
teins with long half-life this can result in masking of the phenotype for one or more cycles. To circumvent this 
additional treatment with rapamycin later in the life cycle or prolonged exposure to rapamycin might be explored. 
Other regulation systems however based on RNA or protein stability might be more suitable in these circum-
stances even though they are more variable in the regulation achieved. Alternatively, protein mislocalisation 
by knock-sideways approaches might be employed to study the function of proteins translated early in the life 
cycle. However, this system will not work for secreted proteins or those rendered dysfunctional by addition of 
multiple FKBP-tags at the N- or C-terminus12. For the study of gene products expressed during trophozoite and/
or schizont stages of the parasite and their function, the DiCre system is able to achieve an unparalleled level of 
regulation with near 100% loss of the gene in one replication cycle, making it the system of choice.
We believe the toolkit of plasmids presented here will lead to the speedy generation of DiCre-expressing trans-
genic parasites allowing for the rapid and efficient rapamycin-inducible excision of genes and the study of their 
function during one growth cycle. We envisage the toolbox will be used to generate DiCre recombinase-expressing 
parasites in strains showing drug resistance, in strains with defined red cell invasion pathways, recently adapted 
field isolates and in strains with the potential to undergo gametocytogenesis and transmission to mosquitoes, 
thereby opening the possibility of studying gene product function in parasites during the mosquito life cycle in 
an inducible manner.
Methods
Parasite culture and transfection. P. falciparum parasites were grown in vitro in RPMI 1640 medium 
containing 0.5% w/v AlbumaxII as described42. Parasites were synchronised by purifying schizont stages using 
a 70% Percoll gradient, before allowing reinvasion to occur, and followed by sorbitol treatment. All parasites 
used in this study were derived from the 3D7 clone, including the control 1G5DC strain13. Plasmids were intro-
duced into purified schizont stage parasites by electroporation using an Amaxa 4D-Nucleofector™ (Lonza) as 
previously described43. For transfections with reporter plasmids to be maintained episomally 10 μg of DNA was 
electroporated and cultures were selected continuously with 2.5 μg/ml of blasticidin-S-HCl. For generation of 
marker-free, DiCre transgenic parasites 20–30 μg of CRISPR/Cas9 plasmids and 60 μg of linearised rescue plas-
mids were electroporated. Selection was applied one day after transfection with 5 nM WR99210 (a kind gift of 
Jacobus Pharmaceuticals) for four days. Following establishment of transgenic parasites, the cultures were treated 
with 1 μM 5-fluorocytosine (5-FC) provided as clinical grade Ancotil® (MEDA) for one week before parasite 
cloning by limiting dilution. To induce DiCre recombinase mediated excision of DNA, early ring stage parasites 
were treated with rapamycin (stock solution was 200 μM in DMSO), before being washed in warm RPMI 1640 
medium and returned to culture.
Cloning of CRISPR/Cas9 plasmids and insertion of guide RNA sequences. The 
pDC2-Cas9-U6-hdhfr vector27 (GenBank accession number KY574493) was modified by replacing the hdhfr 
with hdhfr-yfcu. hdhfr-yfcu was amplified from pL003428 as three overlapping PCR products using primer pairs 
DHFRyFCUfor/Y1rev, Y1for/Y2rev and Y2for/DHFRyFCUrev. PCR products were purified and used at an equi-
molar ratio as template in the subsequent PCR reaction with primer pair DHFRyFCUfor/DHFRyFCUrev. The 
1746 bp product was gel-extracted and cloned into pDC2-Cas9-U6-hdhfr vector using NcoI/SacII sites resulting 
in plasmid pDC2-Cas9-hDHFRyFCU. For generating a CRISPR/Cas9 vector with a different positive selection 
we introduced into pDC2-Cas9-U6-hdhfr a pac-yfcu cassette replacing the hdhfr cassette. The gene for puromycin 
N-acetyltransferase (pac) was amplified from mPAC-TK (kind gift of Alex Maier) using primer pair PACforNcoI/
PACrev(int). The yfcu gene was amplified from pDC2-Cas9-hDHFRyFCU using primer pair Linkerintfor/
DHFRyFCUrev. The pac-yfcu fusion gene was finally generated by overlapping extension PCR and cloned into 
pDC2-Cas9-U6-hdhfr using NcoI/SacII restriction sites.
Potential guide RNA sequences were identified using Protospacer software (www.protospacer.com, versions 
0.0.1 alpha and 0.1.0 beta44). A pair of complementary oligonucleotides corresponding to the 19 nucleotides clos-
est to the identified PAM sequence was synthesized, phosphorylated using T4 polynucleotide kinase, annealed 
and ligated into pDC-Cas9-hDHFRyFCU digested with BbsI. To generate compatible, sticky ends between the 
annealed primer pair encoding the guide RNA and the BbsI digested vector the forward oligonucleotide had 
5′-ATTG added to the 19 nucleotides corresponding to the guide RNA whereas the compatible oligonucleotide 
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had a 5′-AAAC overhang added (see supplementary Table S3). In this way guide RNAs for targeting p230p were 
assembled using oligonucleotide pairs 115for/rev and 120for/rev and cloned into pDC-Cas9-hDHFRyFCU 
resulting in CRISPR/Cas9 plasmids pDC115 and pDC120 respectively. In order to target the pfs47 locus guide 
RNA oligonucleotide pair 287for/rev was phosphorylated, annealed and ligated into pDC-Cas9-hDHFRyFCU 
resulting in vector pDC287.
Construction of rescue plasmids carrying a DiCre recombinase expression cassette. The plas-
mid carrying the ORFs for the Cre59 and Cre60 domains of the DiCre recombinase fused to nuclear targeting 
sequences17 as well as all the P. falciparum-specific 5′ and 3′-regulatory elements is based on pBS_DC_hsp86/
BiP5′13. Homology regions for p230p were amplified from 3D7 genomic DNA using primer pairs p230pF5for/
p230pF5rev and p230pF6for/ p230pF6rev and inserted into pBS_DC_hsp86/BiP5′ using restriction sites SacI/
AflII and SpeI/KpnI, respectively, yielding plasmid pBSp230pDiCre. Homology regions of the pfs47 locus were 
amplified using primer pairs CVO115/CVO116 and CVO117/CVO118 and inserted using restriction sites SacI 
and SpeI/KpnI, respectively, resulting in pBLD466 (synonymously named pBSPfs47DiCre). For transfection of 
3D7 schizonts 60 μg of pBSp230pDiCre and pBSPfs47DiCre were linearised with ScaI for 3 h at 37 °C before heat 
inactivation at 80 °C for 20 min. 20–30 μg of single guide RNA plasmids were added and the plasmid mixture 
ethanol precipitated, washed and resuspended in 10 μl sterile 10 mM Tris, 1 mM EDTA (TE) buffer.
Cloning of reporter plasmid pHH3-SP-loxPint-GFP-loxP. pHH3-SP-loxPint-GFP-loxP reporter plas-
mid is based on vector pHH3bsdMSP3promGFP45, 46 which was digested with AvrII/SacII to release GFP. A DNA 
cassette encoding the MSP3 signal peptide - loxPint - gfp ORF sequence –loxP was amplified with primer pair 
MSP3SPfor/GFPloxPrev from transgenic A3-5 parasites after rapamycin treatment. The A3-5 strain is an induc-
ible Δmsp3Δmsp6 parasite strain in which both msp genes are replaced with gfp after DiCre-mediated excision, 
only maintaining the first 110 bp of the msp3 ORF which encode the signal peptide sequence (Knuepfer and 
Holder, unpublished). The PCR product was purified, digested with NheI/SacII and ligated into pHH3bsdMSP-
3prom resulting in the desired reporter plasmid. All constructs were verified by DNA sequencing.
Nucleic acid extraction and polymerase chain reaction. For DNA extraction total cell pellets were 
first treated with 0.15% saponin in PBS for 10 min on ice, then washed in PBS before DNA was extracted using 
a QIAamp DNA Blood Mini kit (Qiagen). For diagnostic PCR amplification we used GoTaq® (Promega) DNA 
master mix; for amplification of fragments used in construct design we used Phusion® high fidelity DNA poly-
merase (NEB).
SDS-PAGE and immunoblotting. Parasite lines were treated with rapamycin or DMSO at early ring stage 
and schizonts were purified by Percoll gradient ~40 h later. Schizont pellets were lysed in SDS sample buffer con-
taining 100 mM DTT before protein separation on precast Bis Tris NuPAGE polyacrylamide gels and transferred 
to nitrocellulose membranes by electroblotting. Blots were blocked overnight and incubated first with anti-GFP 
antibody (Roche) 1:1000 followed by horseradish peroxidase-conjugated secondary antibody (Biorad). Bands 
were detected using ECL Plus Western blotting reagent (GE Healthcare) and Kodak BioMax MR film. The same 
blots were subsequently incubated with anti-MSP2 antibody mAb113.147.
Fluorescence and FACS analysis. Parasite cultures were treated with rapamycin or 0.05% DMSO at early 
ring stage; schizonts were purified 40 h later using a Percoll gradient. Live, purified schizonts carrying the reporter 
plasmid and expressing GFP were visualised using a Nikon Eclipse Ni microscope with LED-illumination and a 
63x Plan Apo λ NA 1.4 objective. Images were taken using an Orca Flash 4 digital camera controlled by Nikon 
NIS Elements AR 4.30.02 software. To quantitate excision rates by flow cytometry GFP reporter-expressing 
parasite lines were treated with rapamycin or DMSO, and purified 40 h later as described above before being 
stained with Hoechst 33342 at 5 μg/ml for 10 min. Stain was removed and percent GFP-positive schizonts was 
determined in three separate experiments using a BD FACSAria™ Fusion and BD FACSDiva software v8.0.1. 
Percentage excision rate was determined as follows: 100 − (% GFP positive after rapamycin treatment/% GFP 
positive after mock treatment) × 100. All reporter lines were maintained using 2.5 μg/ml blasticidin-S-HCl 
throughout.
SNP analysis of DNA regions used for homologous recombination. Open reading frame and 
5′UTR DNA sequences of pfs47 and p230p were obtained from PlasmoDB (www.plasmodb.org) and aligned 
using ClustalW in BioEdit (www.mbio.ncsu.edu/bioedit/bioedit.html). Of the sequences for 10 laboratory lines 
available we chose 8, excluding V1_S due to large sequence gaps and the IT line due to multiple frame shifts 
in pfs47 ORF. We chose further to analyse, align and display 19 sequences obtained from field isolates from 
French Guiana as both ORF and 5′UTR sequences were complete without sequencing gaps. In addition, we 
analysed SNPs found in HRs from ORF sequences in data available from the Pf3K Project (2015): pilot data 
release 4 (www.Malariagen.net/data/pf3k-4). Polymorphisms in the 5′UTR region of pfs47 used in HR1 in 
pBSPfs47DiCre were analysed using a total of 202 laboratory lines and field isolate sequences available on 
PlasmodDB.
Data availability statement. All plasmids and transgenic P. falciparum parasites described in this study 
are available upon request.
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